Early Post-marketing Study of Eliquis (Apixaban)
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 19 Aug 2016
Price : $35 *
At a glance
- Drugs Apixaban (Primary)
- Indications Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 15 Aug 2016 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 16 Apr 2015 Planned number of patients changed from 50 to 25, according to to ClinicalTrials.gov record.
- 16 Apr 2015 Planned End Date changed from 1 Jun 2016 to 1 Nov 2016, according to to ClinicalTrials.gov record.